title: Increased serum C3 levels in Crry transgenic mice partially abrogates its complement inhibitory effects.
abstract: Complement receptor 1-related gene/protein y (Crry) is a potent murine complement regulator that inhibits C3 convertases. Transgenic mice that overexpress soluble Crry (sCrry), directed systemically by the metallothionein-I promoter, have been used as an animal model for chronic blockade of complement activation. Recently we have found that alternative pathway (AP) activity in Crry transgenic mice was not inhibited as much as expected. To elucidate the mechanism of this effect, we evaluated the AP activities and levels of sCrry and AP complement components in transgenic and non-transgenic mice. In transgenic mice, expression of sCrry was induced by feeding zinc sulphate solution to 70.1 +/- 42.7 micro g/ml mean serum level. Its corresponding level of purified sCrry inhibited 49% of AP activity of normal mice serum; however, the actual AP activities in transgenic mice were not decreased when compared to non-transgenic mice (130.2 +/- 9.0%versus 113.0 +/- 35.4%). Expressed sCrry was functional, as immunoprecipitation and removal of sCrry from transgenic sera with rabbit anti-Crry polyclonal antibody resulted in enhanced AP activity, consistent with initial levels of sCrry. We then compared the changes to C3, factor B, factor H and factor D serum levels in transgenic and non-transgenic mice after induction of sCrry expression. Of these only C3 was increased after zinc feeding in transgenic mice compared to non-transgenic mice (142.8 +/- 14.1%versus 121.4 +/- 15.1%, P = 0.023). These results suggest that the inhibitory effect of chronic exposure to sCrry is compensated by concomitant alteration in C3 levels. This result also suggests the presence of a complement regulatory protein controls the level of serum C3, which has potential importance in the design and interpretation of studies involving chronic use of complement inhibitors.
authors.affiliation: Department of Laboratory Medicine, Hallym University College of Medicine, Anyang, Korea. kangheejung@hallym.or.kr
authors.forename: H J
authors.initials: HJ
authors.lastname: Kang
authors.forename: L
authors.initials: L
authors.lastname: Bao
authors.forename: Y
authors.initials: Y
authors.lastname: Xu
authors.forename: R J
authors.initials: RJ
authors.lastname: Quigg
authors.forename: P C
authors.initials: PC
authors.lastname: Giclas
authors.forename: V M
authors.initials: VM
authors.lastname: Holers
mesh_terms: D000818:Animals; D003176:Complement C3 / Q000378:metabolism*; D011415:Complement Factor B / Q000032:analysis; D011416:Complement Factor D / Q000032:analysis; D017242:Complement Factor H / Q000032:analysis; D003170:Complement Pathway, Alternative; D005434:Flow Cytometry; D015870:Gene Expression; D051379:Mice; D008822:Mice, Transgenic; D011951:Receptors, Complement / Q000032:analysis / Q000235:genetics / Q000378:metabolism*; D017463:Receptors, Complement 3b; D015032:Zinc / Q000008:administration & dosage; D015054:Zymosan
chemical_list: D003176:Complement C3; C081470:Cr1l protein, mouse; D011951:Receptors, Complement; D017463:Receptors, Complement 3b; D017242:Complement Factor H; D015054:Zymosan; D011416:Complement Factor D; C493491:complement factor D, mouse; D011415:Complement Factor B; D015032:Zinc